StemRIM

StemRIM FCF/Debt

The Free Cash Flow to Debt Ratio of StemRIM (4599.T) as of Oct 16, 2026 is 213,741.05 %. In the previous year, Free Cash Flow to Debt Ratio was -38,259.72 % — a change of -658.66% (higher).

FCF/Debt

213,741.05 %

YoY

-658.66%

Last updated:

Free Cash Flow to Debt Ratio of StemRIM is 2023 213,741.05 % . Free Cash Flow to Debt Ratio of StemRIM was 2022 -38,259.72 % . It decreases by -658.66% higher compared to the previous year.

The StemRIM FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2019
-6,201.13 JPY
Jan 1, 2020
4,349.22 JPY
Jan 1, 2021
-9,040.59 JPY
Jan 1, 2022
-38,259.72 JPY
Jan 1, 2023
213,741.05 JPY
The StemRIM FCF/Debt history
YEARFCF/DebtYoY
213,741.05 %-658.66%
-38,259.72 %+323.20%
-9,040.59 %-307.87%
4,349.22 %-170.14%
-6,201.13 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

StemRIM Stock analysis

What does StemRIM do? StemRIM Inc is a biotechnology company based in Ibaraki-shi, Japan, operating within the Health Care sector. The company focuses on the research and development of regeneration-inducing medicines, specifically developing pharmaceuticals that promote functional regeneration and healing of damaged biological tissues without the use of living cells or tissues. StemRIM Inc went public via an IPO on August 9, 2019, and currently employs 44 full-time staff members. The company's primary product is a stem cell regeneration-inducing medicine, which aims to deliver therapeutic effects similar to regenerative medicine through oral administration alone, eliminating the need for live cell or tissue transplantation. StemRIM Inc maintains a website at stemrim.com, though specific details about its product development stage, clinical trials, or commercialization status are not provided in the available information. The company's headquarters are located in Ibaraki-shi, and it is listed on the Tokyo Stock Exchange under the ticker 4599.T with ISIN JP3399690001. No additional details about its founding year, key personnel, acquisitions, or financial figures are included in the provided data. StemRIM is one of the most popular companies on Eulerpool.

Frequently Asked Questions about StemRIM stock

Free Cash Flow to Debt Ratio of StemRIM is 213,741.05 % in 2023.

Free Cash Flow to Debt Ratio of StemRIM changed from -38,259.72 % to 213,741.05 %, representing a -658.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio StemRIM since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's StemRIM with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — StemRIM

All Key Metrics — StemRIM